Filing search / Inhibrx Biosciences, Inc. / "Raw Materials"

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

clinical trials and the ability of the Company’s third party manufacturers to provide the required raw materials, antibodies and other biologics

DEFA14A

INBX Inhibrx Biosciences, Inc.

20 May 24

Additional proxy soliciting materials

9:48pm

party manufacturers to provide the required raw materials, antibodies and other biologics for the Company’s preclinical research and clinical trials

8-K

INBX Inhibrx Biosciences, Inc.

17 May 24

Other Events

5:29pm

therapeutic candidates through clinical trials and the ability of the Company’s third party manufacturers to provide the required raw materials, antibodies

DEFA14A

INBX Inhibrx Biosciences, Inc.

17 May 24

Additional proxy soliciting materials

4:25pm

manufacturers to provide the required raw materials, antibodies and other biologics for the Company’s preclinical research and clinical trials in light

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

9 May 24

Inhibrx Reports First Quarter 2024 Financial Results

4:08pm

the required raw materials, antibodies and other biologics for the Company’s preclinical research and clinical trials in light of current market

8-K

EX-99.1

vc34 g8yxl

8 May 24

Other Events

4:42pm

DEFM14A

hbv5xue35 13

26 Apr 24

Proxy related to merger

4:06pm

DEFA14A

5oete gk2

12 Mar 24

Additional proxy soliciting materials

4:05pm

8-K

k4k3js8u4tt

12 Mar 24

Other Events

4:02pm

8-K

EX-99.1

03p8b ia22kkgn01

28 Feb 24

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

9:12am

DEFA14A

otixm vj5e

6 Feb 24

Additional proxy soliciting materials

4:30pm

DEFA14A

43sri

23 Jan 24

Additional proxy soliciting materials

5:25pm

DEFA14A

iaqq5096lsmh2p3

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

EX-99.1

3btn0jqzusxvw17y00s9

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

dbo50e7z5jwee3y

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

xrcfv nq9ntid

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-99.1

56xxh0 7yug8ouw93

9 Nov 23

Inhibrx Reports Third Quarter 2023 Financial Results

4:03pm